| 概要 |
Uterine leiomyosarcoma is a highly aggressive and lethal disease. Even after comprehensive staging or cytoreductive surgery, followed by multidisciplinary therapies, many patients relapse and finally ...die of this disease. These poor outcomes associated with uterine leiomyosarcoma can be explained, in part, by the rarity, unknown etiology, and highly divergent genetic aberrations of the disease. Significant advances in molecular biology and genetic research have allowed better identification of the molecular signatures of leiomyosarcoma and may help to establish an optimal treatment strategy for this disease. The clinical features, treatments, genetic profiles, and omics-based studies of specific biomarkers for leiomyosarcoma are reviewed in this article.
子宮平滑筋肉腫は高悪性度で予後不良な腫瘍である．手術・放射線・化学療法を含めた集学的治療が施行されても，多くの症例は再発後に原病死に至る．予後不良である背景には，単一ではなく多数の遺伝子変異のためがん化機序が不明瞭なうえに，稀少性故に確立した治療戦略を確立しづらい事項が存在する．一方で，近年の分子生物学的解析手法の発展に伴い，子宮平滑筋肉腫の特性に関する研究が進行している．本稿では我々が導入したOMICS 解析の結果も併せて，子宮平滑筋肉腫の分子生物学的特性・疫学・治療につき概説したい．続きを見る
|
Mendeley出力
